Lonza Group announces expansion plans in microbial fermentation
In order to cope with the increasing demand for microbial fermentation services, Lonza has committed to an expansion of its Kourim (CZ) facility. With the completion of this invest-ment totalling CHF 85 million, the fermentation capacity will be increased by 50% and new Downstream-Processing capabilities and supporting utilities will be added. The cGMP compliant plant is due to come on stream in the fourth quarter of 2003.
“We are extremely pleased to assure our customers access to Lonza’s world class facilities and expertise in microbial fermentation,” says René Imwinkelried, Head of Lonza Biotec. “The decision to expand our capacity and capabilities in cGMP microbial fermentation underscores Lonza’s commitment to strengthen its leadership position. The new plant forms part of a global expansion program in our biotechnology custom manufacturing services.”
Lonza Biotec is part of Lonza Group and is the leader in contract development and manufacturing of therapeutic ingredients and intermediates based on its 20 years of experience in microbial fermentation. The company undertakes specialized services for the pharmaceutical, biotechnology and nutrition industries. With headquarters in Basel (CH), Lonza Biotec operates R&D and cGMP multi-product manufacturing facilities in Visp, Switzerland and Kourim, Czech Republic.
Topics
Organizations
Other news from the department business & finance
These products might interest you
Milli-Q® Services / MyMilli-Q™ by Merck Life Science
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online
Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.